Hints and tips:
Related Special Reports
...Gareth Powell, head of healthcare at specialist fund manager Polar Capital, said mRNA was following previous platforms such as antibodies, in which investors would get excited about developers initially...
...Brussels has accused Illumina of using “delay tactics” to prevent a speedy ruling on whether the world’s biggest gene sequencing company should be forced to divest cancer test developer Grail....
...Despite Sandoz’s incursion into Humira’s territory, generics manufacturers remain cautious in their optimism....
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...Contracts were concluded with eight vaccine developers, providing as many as 4.2bn doses....
...It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...The Swiss pharmaceuticals group is following many rivals to focus its operations on higher-value innovative treatments rather than the cheaper off-patent drugs made by Sandoz, including generic versions...
...Too few and the character looks generic. Some academic research, and intuition, suggests we prefer to inhabit a photorealistic version of ourselves online....
...Access to long-acting drugs in poorer nations with high HIV rates remains patchy, despite the signing of licences for their generic manufacture....
...A blockbuster drug developed by US pharmaceutical group Merck to treat Covid-19 has been linked to mutations transmitted when the coronavirus spreads between patients, a finding that will increase scrutiny...
...EU regulators will order US biotech Illumina to sell cancer test developer Grail after it bought the $8bn company without the approval of Brussels, according to three people with direct knowledge of the...
...New York-listed Illumina and Brussels have been locked in a legal fight since 2021 when the US company proceeded with the purchase of cancer test developer Grail even as EU regulators were examining whether...
...Illumina bought cancer test developer Grail for $8bn in 2021, even though US and EU authorities complained the US gene sequencer could deny crucial inputs to Grail’s rivals....
...Skyscrapers, though, once New York’s signature building type, have become generic and ubiquitous. But a new Brooklyn waterfront is coalescing....
...Big Pharma has always bought out small drug developers to restock its pipelines. Some emerging health science companies aspire to be the next Amgen, which has a market capitalisation of $120bn....
...The company, whose four approved oncology treatments generated $2bn in sales last year, should help the pharmaceutical company offset some of an expected decline in revenue as the Covid vaccine boom fades...
...The 87-year-old activist investor led a shareholder campaign that focused on Illumina’s “reckless decision” to close its $8bn acquisition of cancer test developer Grail in 2021 against the wishes of EU and...
...Several of the world’s biggest pharmaceutical companies are fighting shareholder proposals to force them to disclose information on their use of a controversial patent strategy that can delay rivals from...
...The vote to oust Thompson, a former Microsoft chair and director, follows Icahn’s campaign that focused on Illumina’s “reckless decision” to close its $8bn acquisition of cancer test developer Grail in 2021...
...Icahn alleges that Thompson and deSouza championed a “reckless decision” to close Illumina’s $8bn acquisition of cancer test developer Grail in 2021 against the wishes of EU and US antitrust regulators....
...Generics have been the métier of Teva rather than genetics. It is here that the story starts darkening....
...Earlier on Monday, French pharmaceutical company Sanofi struck a deal to buy Type-1 diabetes treatment developer Provention Bio for $2.9bn, in a bid to bolster its drug pipeline after facing pressure from...
...The case is one of many challenges the company has faced to what the Dutch Pharmaceutical Accountability Foundation calls its “goose with golden eggs”....
...Generic data from the web is no longer good enough to push the performance of AI models, according to developers....
...Bourla said reports that Beijing was negotiating with Pfizer to allow local manufacturers to produce generic versions of the drug for distribution were not correct....
International Edition